NCT06745076View on ClinicalTrials.gov

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

March 6, 2025

Primary Completion Date

January 3, 2032

Study Completion Date

January 3, 2033

Conditions
Advanced Hodgkin LymphomaClassic Hodgkin LymphomaLugano Classification Stage III Hodgkin Lymphoma AJCC v8Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Dacarbazine

Given IV

DRUG

Doxorubicin

Given IV

PROCEDURE

Echocardiography Test

Undergo echocardiography

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA scan

BIOLOGICAL

Nivolumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

DRUG

Vinblastine

Given IV

OTHER

Questionnaire

Complete questionnaire

Trial Locations (2)

10065

NOT_YET_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER